Question special
Moderator

Yesterday the FDA approved marketing of the first direct-to-consumer genetic test for 23andme's Bloom Syndrome test (fda.gov/NewsEvents/Newsroom/Pr...). What are the implications both for testing for this syndrome and for future direct-to-consumer tests?